PAPER Hedden T, Mormino EC, Amariglio RE, Younger AP, Schultz AP, Becker JA, Buckner RL, Johnson KA, Sperling RA, Rentz DM
SEARCH RESULTS
331008 RESULTS
PAPER Sato N, Okochi M, Shinohara M, Thinakaran G, Takeda S, Fukumori A, Shinohara-Noma M, Mori-Ueda M, Hamada H, Takeda M, Rakugi H, Morishita R
Differential regulation of amyloid precursor protein/presenilin 1 interaction during Ab40/42 production detected using fusion constructs.
PLoS One. 2012;7(11):e48551. PubMed: 23152781Guoping Feng
MITCambridge, United States
Ivan Maksimovich on New Strategies for Early Diagnosis of AD
COMMENT Long before AD symptoms, perhaps even in childhood (congenital causes cannot be excluded), people with a high likelihood of acquiring AD show degeneration of the brain capillary bed (1,2). This is manifested in reduction of the capillaries in the temporal
Elizabeth Mormino on Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia.
COMMENT In this paper, La Joie et al. provide convincing evidence for distinct patterns of brain changes (atrophy, hypometabolism, and amyloid deposition) across different brain regions in Alzheimer’s disease. Although the presence of regional discrepancies requi
PAPER La Joie R, Perrotin A, Barré L, Hommet C, Mézenge F, Ibazizene M, Camus V, Abbas A, Landeau B, Guilloteau D, De la Sayette V, Eustache F, Desgranges B, Chételat G
Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia.
J Neurosci. 2012 Nov 14;32(46):16265-73. PubMed: 23152610Kristel Sleegers on Enter the New Alzheimer’s Gene: TREM2 Variant Triples Risk
COMMENT These studies provide further evidence that the genetic architecture of Alzheimer's disease does indeed include rare variants of intermediate penetrance, analogous to our work on rare variants in the GRN (Brouwers et al., 2008) and CLU genes (Bettens
Sylvain Lesne on Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
COMMENT This new report from Kaj Blennow and Oskar Hansson's group appears to support our own findings that soluble α-synuclein levels are increased in brains of subjects with AD (Larson et al., 2012). Whether this elevation corresponds to a "leakage of
David Sulzer on Development and characterization of a new Parkinson's disease model resulting from impaired autophagy.
COMMENT The line of mice introduced in this study indicates what happens when macroautophagy is specifically blocked in dopamine (DA) neurons by deletion of Atg7, a key component of the autophagy machinery. There have been, to my knowledge, three such floxed Atg7
Kristel Sleegers
University of AntwerpAntwerpen, Belgium
PAPER Sulzer D, Mosharov E, Talloczy Z, Zucca FA, Simon JD, Zecca L
Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease.
J Neurochem. 2008 Jul;106(1):24-36. PubMed: 18384642PAPER Lazarou M, Jin SM, Kane LA, Youle RJ
Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase Parkin.
Dev Cell. 2012 Feb 14;22(2):320-33. PubMed: 22280891PAPER Ahmed I, Liang Y, Schools S, Dawson VL, Dawson TM, Savitt JM